Top Markets
Coin of the day
Mithra Pharmaceuticals S.A. Mithra Pharmaceuticals S.A.

Mithra Pharmaceuticals S.A.

MITRA
Pozycja w akcjach #30363
Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège,... Mithra Pharmaceuticals SA, established in 1999 and headquartered in Liège, Belgium, specializes in the creation, production, and worldwide commercialization of advanced therapeutic solutions. The company's core focus areas include contraception, the management of menopause, and treatments for hormone-dependent cancers. Its robust development pipeline features Estelle, a combined oral contraceptive that has successfully concluded Phase III clinical trials, and Donesta, an estetrol-based oral hormone treatment currently undergoing Phase III development for menopausal symptoms. Mithra's product portfolio also encompasses Myring, a hormonal contraceptive vaginal ring; Tibelia, a therapy designed to address both menopause and osteoporosis; and Zoreline, a biodegradable subcutaneous implant targeting prostate and breast cancers, as well as various benign gynecological conditions. Furthermore, the company markets NEXTSTELLIS, an established oral contraceptive pill. Their offerings span diverse pharmaceutical formats, including polymeric devices, implants, sterile injectable medications, and hormonal tablets.
Cena akcji
$0.25620952
Ostatnia synchronizacja: 2024-07-23
Kapitalizacja rynkowa
$17.14M
Zmiana (1 dzień)
10.83%
Zmiana (1 rok)
0.00%
Kraj
BE
Handel Mithra Pharmaceuticals S.A. (MITRA)

Kategoria

Zyski dla Mithra Pharmaceuticals S.A. (MITRA)
Zyski w 2026 TTM: 0
Według najnowszych raportów finansowych Mithra Pharmaceuticals S.A., obecny zysk firmy wynosi 0. W roku 2026 firma osiągnęła zysk w wysokości 0, równa się zysku z roku 2026, który wynosił 0. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Mithra Pharmaceuticals S.A. od 2026 do 2026
Zyski na koniec każdego roku
Rok Zyski Zmień
Za mało danych dla podanych dat.
Zyski podobnych firm lub konkurentów